scientific reports

Check for updates

OPEN Construction and validation a nomogram to predict overall survival for colorectal signet ring cell carcinoma

Jian-dong Diao¹, Li-xia Ma², Chun-jiao Wu², Xian-hong Liu², Xiao-yun Su³, Hong-yu Bi⁴, Bo Bao⁴, Hao-wei Yan⁵, Lei Shi⁶[∞] & Yong-jing Yang⁴[∞]

To construct and validate a nomogram to predict the overall survival (OS) of colorectal signet ring cell carcinoma (SRCC). The potentially eligible cases were obtained against the SEER database from 2004 to 2015. Log-rank test and Cox analysis were conducted to identify the independent prognostic factors for predicting OS. The identified prognostic factors were later integrated for the construction of an OS prediction nomogram. Altogether 2904 eligible cases were identified, and the median survival time was 18 (range: 0–155) months. As suggested by multivariate analysis, age, primary site, grade, tumor size, T stage, N stage, M stage, surgery, lymph node dissection and chemotherapy were identified as the independent factors for predicting OS. Afterwards, the above variables were incorporated into the nomogram. The C-index indicated better discriminatory ability of the nomogram than AJCC 8th TNM staging and SEER summary stage systems (both P < 0.001). Calibration plots further showed good consistency between the nomogram prediction and actual observation. The time independent area under the curves (tAUCs) for 3-year and 5-year OS in nomogram were larger than AJCC and SEER summary stage system. The constructed nomogram could potentially predict the survival of colorectal SRCC individuals.

Colorectal cancer (CRC) is the second most common cause of cancer-associated mortality in the United States, and it has posed a great threat to global health¹. In recent years, colorectal signet ring cell carcinoma (SRCC), one of the CRC subtypes², has aroused wide attention. It is extensively reported that, SRCC commonly originates from the undifferentiated colorectal mucosal stem cells; therefore, fast proliferation, low differentiation level, metastasis and diffuse infiltration can be frequently detected^{3,4}. In addition, SRCC is also identified by the AJCC 7th TNM classification system as the independent factor to predict the adverse prognosis⁵. Nonetheless, there are only small case series and case reports available for colorectal SRCC, while information regarding its clinicopathological characteristics and prognostic outcomes remains largely unexplored⁶. In this regard, it is important to precisely estimate the prognosis of SRCC cases, which may facilitate the development of risk-based individualized treatment and the best therapeutic strategies.

TNM stage system is a prevalent method to predict the outcomes in tumor patients through assessing tumor size and location (T), regional lymph node metastasis (N) and distant metastasis (M)⁷. However, TNM classification is not efficient to encompass cancer biology as well as to precisely predict outcomes of colorectal SRCC⁸. In addition, other clinicopathological parameters can also affect prognosis in SRCC patients, including tumor grade, tumor site, race, age and therapy^{4,9}. Hence, it is urgently demanded to establish a novel stage classification involving tumor features and patient status.

As a simple, user-friendly statistical method, nomogram has been uncovered to harbor comparative or even superior predictive capacity over conventional TNM stage systems in various types of malignancies^{10–12}. To be specific, the successful establishment of nomogram should not only consider the prognostic weight of every parameter to calculate the possibility of an outcome but incorporate several independent indicators for optimal

¹Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China. ²Departments of Oncology, Jilin Cancer Hospital, Changchun, Jilin 130012, China. ³School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130012, China. ⁴Department of Radiation Oncology, Jilin Cancer Hospital, Changchun, Jilin 130012, China. ⁵Department of Regeneratve Medicine, School of Pharmacy, Jilin University, Changchun, Jilin 130012, China. ⁶Prevention and Health Care Department, Jilin Cancer Hospital, Changchun, Jilin 130012, China. Zemail: 1256267702@qq.com; yangyongjing1975@163.com

conclusion. Of note, nomograms are capable of accurately estimating survival for individuals via the assessment of vital prognostic factors than TNM stage system^{13,14}. However, as far as we know, there is no such population-based nomogram specifically for colorectal SRCC. To this end, we aimed at constructing and verifying a nomogram for OS prediction in colorectal SRCC based on Surveillance, Epidemiology and End Results (SEER) database.

Materials and methods

Ethics statement. SEER is the greatest cancer database with the highest authoritativeness in North America¹⁵, which includes cancer data through covering nearly 30% of the US populations across different geographic regions that can stand for population diversity¹⁶. To collect related information from this database, the SEER Research Data Agreement (No. 19817-Nov2018) was signed in this study, and data were searched against this database in line with those approved guidelines. The extracted data were publicly accessible and de-identified, and the data analysis was considered as non-human subjects by Office for Human Research Protection, thus, no approval was demanded from institutional review board.

Study population. The eligible cases were screened using the SEER*State v8.3.6 approach (released on August 8th, 2019). In the present work, we included 18 SEER regions between 2004 and 2015. Patients conforming to the following criteria were enrolled: (1) those with primary colorectal SRCC; and (2) those with SRCC diagnosed according to the third version of the International Classification of Disease for Oncology (ICD-O-3; coded as 8490/3). At the same time, patients conforming to any one of the following conditions were excluded from this study: (1) patients with more than one primary tumor; (2) those with clinical diagnosis, or those diagnosed based on autopsy or the death certificate; (3) those with insufficient data like the mode of surgery and AJCC stage; (4) those whose tumor location was not mentioned; (5) those with unavailable information on prognosis. The remaining participants were included into the initial SEER cohort. For establishing and validating the nomogram, the enrolled cases were randomized into the training or validation set.

Covariates and endpoint. The following patient characteristics were analyzed, including gender, age,race, marital status, insurance status, primary site, year of diagnosis, tumor size, grade,T, N, M stage, surgery, lymph node dissection, radiotherapy and chemotherapy. In this study, the single (never married), widowed (having a domestic partner), separated and divorced cases were classified into unmarried category¹⁷. With regard to the primary tumor site, it was divided into cecum–transverse colon (such as appendix, cecum, ascending colon, transverse colon, hepatic flexure), descending colon–sigmoid (like descending colon, sigmoid colon, splenic flexure), multiple, rectum and unknown¹⁸. As for the year of diagnosis, it was classified as 2004–2007, 2008–2011, 2012–2015, in line with previous studies^{19,20}. At the same time, tumor size and age were grouped according to previous articles as well^{21–24}. The cancer stage was classified according to the AJCC 6th classification system that was adapted to SEER-derived patients diagnosed from 2004 to 2015. Meanwhile, the qualified patients were further regrouped in line with the AJCC 8th TNM classification system. In this study, the endpoint was set as overall survival (OS), which referred to the duration between diagnosis and death due to all causes²⁵.

Statistical analysis. Nomogram construction. Categorical variables were compared by Fisher's exact test or chi-square test and expressed in the manner of proportions and frequencies. Univariate analysis was conducted to predict prognosis using the Kaplan–Meier (K–M) approach as well as log-rank test. Upon univariate analysis, variables with *P*-value ≤ 0.1 were screened for multivariate backward stepwise Cox proportional hazard analysis to determine each possible independent risk factor. Additionally, multicollinearity diagnostics in statistical modeling were conducted by evaluating the correlations, variance inflation factors, and eigenvalues. Then, we established a nomogram model (based on identified prognostic factors) to predict 3-year, 5-year OS in the training and validation cohort using the rms package of R. We determined the total nomogram score for every case based on every variable score in the contour diagram for modeling group.

Nomogram validation. The nomogram was validated by determining its discrimination and calibration abilities using the internal (training) as well as external (validation) set, respectively. In addition, we used the concordance index (C-index) for evaluating our model discrimination performance and assessing the difference in the predicting ability between predicted and observed values²⁶. As a result, the higher C-index value indicated the better patient discrimination ability among different prognostic outcomes. Also, we used the Rcorrp.cens package of Hmisc in R software for comparing the different results from the existing 8th TNM classification system and the SEER summary stage system, and utilized C-index to determine them. Using the marginal estimate versus model, plots presenting the calibration of predicted with measured survival outcomes were made, where the 45-degree plot was the optimal model with marked consistency in terms of the outcomes. The Receiver Operating Characteristic (ROC) curves were also plotted to validate the nomogram score. In this study, the bootstrapping re-sampling approach (1000 repetitions) was applied in obtaining the comparatively unbiased estimates and checking interval validation. Statistical analysis was conducted using SPSS19.0 (SPSS Inc., Chicago, USA) and R (version 3.51, www.r-project.org). A difference of P < 0.05 (two-tailed) was deemed to be statistically significant.



Figure 1. Flow chart for patients selection.

Results

Patient characteristics. In total, 2904 qualified subjects who were diagnosed with colorectal SRCC from 2004 to 2015 were enrolled in this research. In addition, 2032 and 872 subjects were assigned into the training and validation cohorts, respectively. The flow chart of data selection was displayed in Fig. 1. Among all the subjects, 50.69% were males, with a median age was 63 years (range: 12–103 years). Most subjects were married (53.99%) and white (81.61%). Cecum–transverse colon (61.95%) was the most prevalent tumor site, followed by rectum (19.42%), descending colon–sigmoid (15.87%) and multiple (1.48%). Tumor size $^{>}5$ cm (42.84%) was the most common. Most cases of colorectal SRCC had advanced clinical stage (T3: 44.42%; T4:45.83%; N2:46.83%) and advanced pathological grade (grade III/IV: 80.65%).Operations were performed on 2568 (88.43%) patients, of which 1728 (59.50%) were total colectomy/ proctectomy. Most patients (79.72%) had more than four lymph nodes removed. More than half of the patients received chemotherapy (58.13%) and only 13.83% patients received radiotherapy. The median survival time was 18.0 months (0–155 months). The 3- and 5-year OS rates were 35.6%, and 28.1%. The demographic and clinicopathological features were listed in Table 1, indicating no significant difference between two groups.

Nomogram construction. Univariate analysis revealed 11 indicators could affect OS (shown in Table 2). Among them, marital status was included as an adjusted variable in the step-wise modeling. Consequently, multivariate analysis showed that age, primary site, grade, tumor size, T stage, N stage, M stage, surgery, lymph node dissection and chemotherapy were independent predictive indicators of OS (all P < 0.05). Multicollinearity diagnostic tests including pair-wise correlations, variance inflation factors plot and eigenvalues plot suggested that severe multicollinearity issues would not exist (Supplemental Figs. 1 and 2). A nomogram for 3- and 5-year OS prediction was constructed according to these independent factors (Fig. 2). Nomogram uncovered that AJCC stage made the greatest contribution to prognosis, followed by surgery, chemotherapy, number of lymph node dissection and age. By adding the scores of each selected variable, the likelihood of survival of the individual patient can be easily calculated.

Nomogram validation. The nomogram was validated internally and externally. In the training and validation cohorts, namely internal validation and external validation cohorts, the OS prediction C-indexes in nomogram were respectively 0.743 (95% CI, 0.730–0.755), 0.730 (95% CI, 0.710–0.751). Furthermore, a comparison was made between the discrimination ability of nomogram with the ability of SEER summary stage and TNM 8th staging classification, indicating that in the training as well as validation set (P<0.001), the nomogram is superior to SEER and TNM 8th staging classification, as shown in Table 3. At last, as shown in Fig. 3, both the internal calibration plot and external calibration plot of the nomogram exhibited good consistency between the predictions and practical results based on the nomogram. Figure 4 showed the relevant ROC of the training and validation cohort. In the training cohort, the time independent area under the curves (tAUCs) of 3– and 5– years OS were 0.830 (0.810–0.850) and 0.840 (0.818–0.862). In the validation cohort, the tAUCs of OS for 3- and 5- years were 0.823 (95% CI: 0.793–0.853) and 0.810 (95% CI: 0.775–0.844), respectively, which were all greater than AJCC and SEER summary stage system. Bootstrapping with 1000 resamples in the training set

Yar a diagnoisInterpret setInterpret setInter	Variables	All patients N (%)	Validation set N (%)	Training set N (%)	P value
2001-200794(133.80)92(33.09)602(34.00)6022088-2011946(33.20)86(3.20)86(3.70)1Insured status96(3.01)75(31.54)628(0.91)7Insured status010 (8.80)57(6.84)1404(6.90)7Age media/inaured2018(8.90)57(6.84)1404(6.90)7Age media/inaured1011 (8.90)49(6.80)979(4.81)1Age media/inaured1516 (52.00)46(5.01)905(5.01,02)6.332561388 (47.80)490(46.90)979 (48.18)1Marind status1396 (40.01)40(6.81)906 (53.91)6.32Marind status1386 (45.01)412 (54.13)106 (53.91)6.32Gender1386 (45.01)412 (43.13)106 (53.91)6.32Marind status142 (24.53)41 (64.31)104 (51.23)1.32Marind status142 (250.891)416 (83.91)1.621.72Make275 (97.11)79 (96.13)166 (81.91)1.72Back275 (97.11)105 (83.81)1.62 (81.91)1.72Other279 (91.51)27 (91.63)38 (19.09)1.72Primary site109 (15.73)167 (15.13)1.621.72Cacuum-transvers colon179 (15.92)27 (16.30)1.621.72Mating consignidi (16.15)17 (15.13)16.151.721.72Carde II/17 (16.10)13 (15.93)16.151.721.72Grade II/17 (16.11)13 (15.93)16.151.72	Year at diagnosis				0.479
2008-01194 (02.85)900 (03.40)904 (03.17)64 (02.19)7Danard staus903 (01.10)275 (01.54)628 (00.91)7Any medical/insored903 (01.10)75 (01.54)628 (00.91)7Ay medical/insored903 (01.00)645 (03.10)1035 (01.82)7Sea565156 (52.00)465 (03.10)1053 (01.82)7Sea156 (02.00)400 (04.87)956 (46.06)7Marial stans136 (60.10)400 (04.87)956 (46.06)7Mariad call138 (66.01)401 (03.70)956 (46.06)7Gender138 (66.01)412 (53.10)914 (45.71)7Gender142 (03.11)414 (05.77)914 (45.71)7Mariad stans142 (03.11)414 (05.77)914 (45.71)10Gender142 (03.11)414 (05.71)914 (45.12)1010Mariad142 (03.11)414 (05.77)914 (45.12)1010Mariad142 (03.11)414 (05.71)914 (45.12)1010Mariad142 (03.11)144 (05.12)104 (11.12)1010Mariad142 (03.11)150 (15.12)101010Mariad142 (03.11)165 (15.12)101010Mariad140 (15.12)140 (10.12)101010Mariad140 (10.12)140 (10.12)101010Mariad140 (10.12)140 (10.12)16.1510Mariad <td< td=""><td>2004–2007</td><td>984 (33.88)</td><td>292 (33.49)</td><td>692 (34.06)</td><td></td></td<>	2004–2007	984 (33.88)	292 (33.49)	692 (34.06)	
2012-015966 (33.26)200 (211)686 (33.76)7Inaured status00Otinissurd/unknown900 (08.90)577 (08.46)1404 (09.09)3Age-1516 (52.20)463 (53.10)1053 (51.82)-Se51516 (52.20)463 (53.10)053 (51.82)Se61516 (52.20)460 (68.00)979 (48.10)Se71388 (47.80)400 (65.87)996 (46.60)Unmarried1336 (46.01)401 (53.71)916 (46.70)Martal status136 (63.01)411 (90.57)916 (48.71)GenderGender1432 (49.31)411 (90.57)196 (48.71)Bak275 (94.71)79 (90.60)196 (45.61)31 (12.10)Bak275 (94.71)79 (90.61)166 (18.94)	2008-2011	954 (32.85)	300 (34.40)	654 (32.19)	
Issered statusImage	2012-2015	966 (33.26)	280 (32.11)	686 (33.76)	
Unisanzd/unknown903 (31.10)275 (31.54)6.28 (30.91)7.Any medicaid/msured2001 (68.90)597 (68.46)1404 (69.90)52.8Age1516 (52.20)463 (53.10)1053 (51.82)7.2 65158 (67.80)463 (53.10)1053 (51.82)7.2 65158 (67.80)404 (65.97)926 (46.06)7.Marital status136 (46.01)400 (45.87)936 (46.06)7.Marital status155 (53.99)47 (54.13)106 (53.94)7.Gender1432 (49.31)41 (50.57)991 (48.77)7.Female1432 (49.31)41 (49.037)196 (45.67)7.Bak275 (9.47)7.9 (9.06)196 (9.65)7.Bak275 (9.47)7.9 (9.06)196 (9.65)7.Other259 (8.92)88 (10.99)116 (55.00)7.Other259 (8.92)88 (10.99)116 (55.00)7.Other1799 (10.55)527 (60.44)122 (26.04)7.Descending colon-sigmoid169 (15.87)145 (16.83)36 (15.95)Grade JUT43 (14.84)10 (1.51)33 (1.90)1.Grade JUT173 (59.00)63 (72.91)136 (15.91)1.Unknown393 (13.40)160 (1.81)31 (4.21)1.Grade JUT124 (26.81)39 (16.85)1.1.Unknown393 (13.40)63 (72.91)161 (5.10)1.Grade JUT124 (16.85)48 (16.85)48 (16.85)1.Grade JUT <t< td=""><td>Insured status</td><td></td><td></td><td></td><td>0.736</td></t<>	Insured status				0.736
Any medicaid/insured2001 (08.90)SP7 (08.46)1404 (09.09)0.52Age0.5280.530.530.530.530.530.53Se51388 (47.80)409 (46.90)979 (48.18)0.940.940.94Marital status0.04 (68.37)930 (60.00)0.050.95Marital status1336 (64.20)400 (64.37)1930 (60.00)0.070.070.07Marital status1368 (35.90)412 (54.13)1096 (53.94)0.07 <td< td=""><td>Uninsured/unknown</td><td>903 (31.10)</td><td>275 (31.54)</td><td>628 (30.91)</td><td></td></td<>	Uninsured/unknown	903 (31.10)	275 (31.54)	628 (30.91)	
AgeImageImageImageImageImageImageImageImage2651388 (47.80)463 (53.10)1053 (51.82)ImageIma	Any medicaid/insured	2001 (68.90)	597 (68.46)	1404 (69.09)	
<651516 (S2.20)463 (33.10)1053 (51.82)1≥ 651388 (J7.80)400 (45.07)979 (48.18)0Marital status1336 (46.01)400 (45.87)936 (46.06)1Married1568 (53.99)472 (54.13)1096 (53.94)1Gender1432 (49.31)441 (50.57)991 (48.77)0Female1432 (9.31)441 (50.57)991 (48.77)0Male1472 (50.69)431 (49.43)1041 (51.23)0Race275 (9.47)79 (9.06)196 (9.55)1Black275 (9.47)79 (9.06)196 (9.51)0Other2930 (81.61)705 (80.85)1665 (81.94)1Primary site2370 (81.61)705 (80.85)1665 (81.94)1Ccama-transverse colon1799 (61.95)527 (60.44)1272 (62.60)1Descending colon-sigmoid461 (15.87)145 (16.63)316 (15.55)1Muliple43 (148)10 (1.15)33 (1.62)11Grade177 (25.96)63 (7.22)110 (5.41)21Grade173 (5.96)63 (7.22)110 (5.41)21Grade II/I/V2342 (80.55)697 (79.33)1645 (80.95)1Unknown389 (13.40)112 (12.43)874 (45.01)1Tumor size110 (40.63)40 (4.23)83 (4.00)1Tumor size110 (40.63)35 (4.01)65 (3.22)11Ta sige120 (44.24)370 (42.43)874 (45.01) <td>Age</td> <td></td> <td></td> <td></td> <td>0.528</td>	Age				0.528
≥651388 (47.80)409 (46.90)979 (48.18)100Martial statusII00 (45.87)976 (46.60)0244Unmarried1353 (46.01)400 (45.87)936 (46.60)10Martied1568 (53.99)472 (54.13)1096 (53.94)10GenderI1432 (49.31)411 (50.57)991 (48.77)70Female1432 (29.31)411 (50.77)991 (48.77)0.272Black1273 (50.69)1566 (51.94)1041 (51.23)10Race275 (94.77)79 (90.6)196 (96.5)1.665 (51.94)Other257 (94.77)79 (90.6)156 (56.19.40)1272 (50.60)Other259 (92.2)88 (10.09)117 (84.2)0.10Cecum-transverse colon199 (61.55)527 (60.44)127 (26.20)1.02Descending colon-signoid461 (15.87)145 (16.63)316 (15.55)1.02Multiple44 (1.48)10 (1.15)33 (1.62)1.02Carde III7037 (12.7)116 (50.18)38 (19.09)1.02Unknown37 (12.7)110 (51.1)31 (1.62)1.02Grade III71V2342 (80.55)63 (72.2)110 (51.1)31Unknown389 (13.40)112 (12.84)37 (13.63)1.02Tumor size170 (50.69)50 (11.83)81 (94.03)1.02S 5 cm179 (40.60)56 (12.90)63 (72.1)1.02Tumor size16 (0.55)4 (0.46)12 (0.59)61T stage10 (14.53)37 (1	<65	1516 (52.20)	463 (53.10)	1053 (51.82)	
Martial statusInInInInInInUnmarried1366 (63.09)472 (54.13)1096 (53.94)IMarried1568 (53.99)472 (54.13)1096 (53.94)IGenderInIn0.73Female1432 (9.31)441 (50.57)991 (48.77)IMale1472 (50.69)431 (49.43)1041 (51.23)IRaceInIn0.27Black275 (9.47)79 (9.06)196 (9.65)IOther259 (8.2)88 (10.09)171 (42.0)IOther259 (8.2)88 (10.09)171 (42.0)IOther159 (8.2)152 (6.04)1272 (6.60)IDescending colon-signoid461 (18.77)145 (10.13)31 (16.2)IMultiple43 (1.49)10 (1.15)33 (16.2)IIGradeInInInIIGrade IIIIV242 (80.5)697 (79.3)165 (80.95)IGrade IIIIV242 (80.5)697 (79.3)164 (80.95)IUnknown389 (13.40)12 (12.83)33 (16.80)ITumor sizeIn142 (16.20)33 (16.20)IS ⁵ cm160 (55)410 (13.19)33 (12.0)ITumor sizeIn142 (16.20)33 (16.20)IS ⁷ tageInIn120 (14.23)33 (16.20)ITumor sizeIn142 (16.20)160 (12.91)IS ⁷ tageInInIn <t< td=""><td>≥65</td><td>1388 (47.80)</td><td>409 (46.90)</td><td>979 (48.18)</td><td></td></t<>	≥65	1388 (47.80)	409 (46.90)	979 (48.18)	
Unmarried1336 (46.01)400 (45.87)936 (46.06)1Married1568 (53.99)472 (54.13)1096 (53.94)0.373Gender1432 (94.31)441 (60.57)991 (48.77)0.373Female1432 (90.30)431 (94.34)1041 (51.23)0.373Male1472 (50.69)431 (94.34)1041 (51.23)0.327Black257 (94.7)79 (90.6)156 (65 (1.94)0.327White2370 (81.61)705 (80.85)1665 (81.94)0.10Other257 (94.7)79 (90.6)156 (56 (1.94)0.10Cecum-transverse colon1799 (61.55)527 (60.44)1272 (62.60)0.10Descending colon-sigmoid461 (15.87)145 (16.63)316 (15.55)1.02Multiple43 (1.48)10 (1.15)33 (1.62)1.020.15Grade172 (50.40)110 (541)21 (1.050.150.15Grade UI/1V242 (3.04)67 (79.93)1645 (80.50)0.15Grade UI/1V243 (1.93)360 (1.28)819 (0.90)0.15Unknown380 (1.30)112 (12.84)277 (13.63)1.02Unknown1179 (14.02)360 (1.28)819 (0.31)0.15Timor size110 (57)40 (4.12)819 (4.13)0.16Unknown160 (5.27)1.00 (5.21)1.001.00Unknown161 (5.75)40 (4.64)12 (0.76)1.00Timor size100 (3.44)35 (4.01)65 (3.20)1.00Timor size100 (3.44)<	Marital status				0.924
Married1588 (53.99)472 (54.13)1096 (53.94)7GenderIII0.373Female143 (24.93.1)441 (50.57)991 (48.77)IMale1472 (20.69)431 (49.43)1041 (51.23)IRaceIII0.327Black275 (94.7)79 (60.85)1665 (81.94)IWhite2370 (81.61)705 (60.85)1665 (81.94)IOther259 (8.92)88 (10.99)171 (8.42)IOther259 (8.92)88 (10.99)171 (8.42)IDescending colon-sigmoid461 (15.87)145 (16.63)316 (15.57)IMultiple43 (1.48)10 (1.15)33 (1.62)IDescending colon-sigmoid461 (15.87)141 (16.03)316 (1.55)IMultiple43 (1.94)10 (1.15)33 (1.62)IIOrknown37 (1.27)14 (1.61)23 (1.13)IIGrade II/IV23 424 (80.50)697 (72.91)1645 (80.95)IIGrade II/IV173 (5.96)63 (7.22)110 (5.41)IIUhknown38 (14.65)112 (12.84)27 (11.53)IIUhknown38 (14.65)112 (12.84)391 (6.80)IIUhknown117 (14.64)300 (12.83)81 (4.93)IIUhknown160 (5.57)4 (0.46)12 (0.59)IITi160 (5.57)4 (1.639)889 (4.57)IITi<	Unmarried	1336 (46.01)	400 (45.87)	936 (46.06)	
GenderImage <th< td=""><td>Married</td><td>1568 (53.99)</td><td>472 (54.13)</td><td>1096 (53.94)</td><td></td></th<>	Married	1568 (53.99)	472 (54.13)	1096 (53.94)	
Female1432 (49.31)441 (50.57)991 (48.77)1Male1472 (50.69)431 (49.43)1041 (51.23)0Race257 (947)79 (9.06)196 (9.65)3270Black257 (947)79 (9.06)196 (9.65)1665 (81.94)1White2370 (81.61)705 (80.85)1665 (81.94)1Other259 (8.92)88 (10.09)171 (8.42)1Primary site709 (61.55)527 (60.44)1272 (62.60)1Descending colon-sigmoid461 (15.87)145 (16.63)316 (15.55)1Multiple43 (1.48)10 (1.15)33 (1.62)1Rectum564 (19.42)176 (20.18)388 (19.09)1Unknown37 (1.27)140 (1.18)23 (1.13)1Grade17173 (5.96)63 (7.22)110 (5.41)1Grade II/IV2342 (80.65)697 (79.93)1645 (80.95)1Unknown294 (80.60)12 (12.84)277 (13.63)1Unknown89 (13.40)12 (12.84)339 (16.60)1Tumor size1012 (12.84)339 (16.60)1T103 (44.24.84)370 (42.33)814 (43.10)1T16 (0.55)4 (0.46)12 (0.59)1T16 (0.55)4 (0.46)12 (0.59)1T16 (0.55)4 (0.46)12 (0.59)1T16 (0.55)4 (0.46)12 (0.59)1T16 (0.35)4 (0.46)12 (0.59)1	Gender				0.373
Male 1472 (50.69) 431 (49.43) 1041 (51.23) 0.327 Race 275 (9.47) 79 (9.06) 196 (9.65) 0 Black 275 (9.47) 79 (9.06) 196 (9.65) 0 White 2270 (81.61) 705 (80.85) 1665 (81.94) 0 Other 259 (8.92) 88 (10.09) 171 (8.42) 0 Descending colon-sigmoid 461 (15.87) 145 (16.63) 316 (15.55) 1 Multiple 43 (1.48) 10 (1.15) 33 (1.62) 1 0 Descending colon-sigmoid 43 (1.48) 10 (1.15) 338 (19.09) 1 0 Grade JUII 71 (7.7) 14 (1.61) 23 (1.13) 0 0 Grade JUIIV 2342 (80.65) 697 (79.93) 1645 (80.95) 1 0 Unknown 389 (13.40) 112 (2.84) 370 (16.3) 0 0 0 Tumor size 0 0 0 0.77 (13.63) 0 0 0 Tumor size 1179 (40.60)	Female	1432 (49.31)	441 (50.57)	991 (48.77)	
RaceImage: stateImage: stateImage: stateImage: stateImage: stateImage: stateBlack275 (947)79 (9.06)196 (9.65)12White2370 (81.61)705 (80.85)1665 (81.94)1Other259 (892)88 (10.09)171 (8.42)0.510Cecum-transverse colon1799 (61.95)527 (60.44)1272 (62.60)1Descending colon-sigmoid461 (15.87)145 (16.63)316 (15.55)1Multiple43 (1.48)10 (1.15)33 (1.62)11Eactum564 (19.42)176 (20.18)388 (10.90)11Unknown37 (1.27)14 (1.61)23 (1.13)11Grade I/IT173 (5.96)63 7 (2.29)164 (5.60)11Unknown389 (13.40)112 (12.84)277 (13.63)11Unknown389 (13.40)112 (12.84)277 (13.63)11Unknown189 (13.40)112 (12.84)87 (45.01)11Unknown189 (13.40)112 (12.84)87 (45.01)11Unknown189 (13.40)112 (12.84)87 (45.01)11Unknown189 (13.40)142 (16.28)39 (16.68)11Unknown160 (55)61 (70.00)166 (52.00)111Unknown16 (15.57)61 (70.00)166 (52.00)1111111111111111	Male	1472 (50.69)	431 (49.43)	1041 (51.23)	
Black275 (9.47)79 (9.6)196 (9.65)IWhite2370 (81.61)705 (80.85)1665 (81.94)IOther259 (8.92)88 (10.09)171 (8.42)SPrimary siteIS27 (60.44)1272 (62.60)ICecum-transverse colon1799 (61.95)527 (60.44)1272 (62.60)IDescending colon-sigmoid461 (15.87)145 (16.63)316 (15.55)IMultple43 (1.48)10 (1.15)33 (1.62)IRectum564 (19.42)176 (20.18)388 (19.09)IUnknown37 (1.27)14 (1.61)130 (1.63)IGrade I/II173 (5.96)63 (7.2)110 (5.41)IGrade I/II/V2342 (80.65)697 (79.33)1645 (80.95)IUnknown389 (13.40)112 (12.84)819 (40.11)ITumor sizeII30 (42.83)874 (43.01)I'5 cm1129 (40.60)360 (41.28)819 (6.82)IIUnknown481 (15.55)40.46)12 (16.52)IITageIIIIIITo Tis160 (5.55)61 (7.00)106 (5.20)IITageIIIIIINageIIIIIINageIIIIIINoS51 (5.75)61 (7.00)106 (5.22)IITageIIIII </td <td>Race</td> <td></td> <td></td> <td></td> <td>0.327</td>	Race				0.327
White2370 (81.61)705 (80.85)1665 (81.94)IOther259 (8.92)88 (10.09)171 (8.42)0Primary site	Black	275 (9.47)	79 (9.06)	196 (9.65)	1
Other259 (8.92)88 (10.09)171 (8.42)1Primary siteIIS27 (60.44)1272 (62.60)ICecum-transverse colon1799 (61.95)527 (60.44)1272 (62.60)IDescanding colon-sigmoid461 (15.87)145 (16.63)331 (62)IMultiple364 (19.42)176 (20.18)388 (19.09)IRectum564 (19.42)176 (20.18)388 (19.09)IOthknown37 (1.27)14 (1.61)23 (1.13)IGrade I/II173 (5.96)63 (7.22)110 (54.1)IGrade I/IIV2342 (80.65)697 (79.93)1645 (80.95)IUnknown389 (13.40)112 (12.84)277 (13.63)IUnknown389 (13.40)112 (12.84)277 (13.63)IUnknown1244 (42.84)370 (42.3)874 (43.01)I'5 cm1244 (42.84)370 (42.3)874 (43.01)IT stage160 (55)4 (0.46)12 (0.59)IT1167 (57.57)61 (7.00)106 (5.22)IT3120 (44.24)35 (40.1)65 (3.20)IT41331 (45.83)371 (42.59)889 (37.5)IT4130 (3.44)35 (40.1)65 (3.20)INageImageImageImageImageImageNa100 (3.44)371 (42.59)889 (3.57)INageImageImageImageImageImageNageImageImageImageIma	White	2370 (81.61)	705 (80.85)	1665 (81.94)	
Primary siteImageImageImageImageImageImageCecum-transverse colon1799 (61.95)527 (60.44)1272 (62.00)ImageDescending colon-sigmoid461 (15.87)145 (16.63)316 (15.55)ImageMultiple43 (1.81)10 (1.15)33 (1.62)ImageMultiple454 (19.42)176 (20.18)338 (19.09)ImageUnknown37 (1.27)14 (1.61)23 (1.13)ImageGradeImageImageImageImageGrade II/I173 (5.96)697 (79.93)1645 (80.95)ImageGrade II/IV2342 (80.65)697 (79.93)1645 (80.95)ImageUnknown389 (13.40)112 (12.84)277 (13.63)ImageTumor sizeImageImageImageImageSc m1179 (40.60)360 (41.28)819 (40.31)ImageUnknown481 (65.5)4 (0.46)12 (0.59)ImageTo sigeImageImageImageImageTo Tis16 (0.55)4 (0.46)12 (0.59)ImageTo Tis167 (57.53)61 (7.00)106 (5.22)ImageTa singeImageImageImageImageNa singeImageImageImageImageNa singeImageImageImageImageNa singeImageImageImageImageNa singeImageImageImageImageNa singeImageImageImageI	Other	259 (8.92)	88 (10.09)	171 (8.42)	
Cecum-transverse colon1799 (61.95)527 (60.44)1272 (62.60)IDescending colon-sigmoid461 (15.87)145 (16.63)316 (15.55)IMultiple43 (1.48)10 (1.15)33 (1.62)IRectum564 (19.42)176 (20.18)388 (19.09)IUnknown37 (1.27)14 (1.61)238 (19.09)IGradeI0.155III (5.41)III (5.41)Grade III/IV2342 (80.65)697 (79.93)1645 (80.95)IUnknown39 (13.04)112 (1.2.84)277 (13.63)ITumor sizeI124 (42.84)370 (42.43)819 (40.31)I'5 cm1179 (40.60)360 (41.28)819 (40.31)II'5 cm1124 (42.84)370 (42.43)874 (43.01)II'5 cm124 (42.84)370 (42.43)874 (43.01)II'5 cm16 (0.55)61 (7.00)106 (5.22)IITageIIIIII'7 cm160 (3.54)371 (42.55)960 (47.24)IITageIIIIIIITageIIIIIIITageIIIIIIII hageIIIIIIITageIIIIIIITageIIIIIIII </td <td>Primary site</td> <td></td> <td></td> <td></td> <td>0.510</td>	Primary site				0.510
Descending colon-sigmoid 461 (15.87) 145 (16.63) 316 (15.55) Multiple 43 (1.48) 10 (1.15) 33 (1.62) 1 Rectum 564 (19.42) 176 (20.18) 388 (19.09) 1 Unknown 37 (1.27) 14 (1.61) 23 (1.13) 0.155 Grade 0.155 0.155 0.155 Grade UII 173 (5.96) 63 (7.22) 110 (5.41) 0.155 Grade UII 173 (5.96) 697 (79.93) 1645 (80.95) 0.882 Grade UIIV 2342 (80.65) 697 (79.93) 1645 (80.95) 0.882 Unknown 389 (13.40) 112 (12.84) 277 (13.63) 0.70 Tumor size 0.882 55 cm 1244 (42.84) 370 (42.43) 874 (43.01) 0.70 Tstage 0.79 145 (55) 4 (0.46) 12 (0.59) 15 Tstage 0.079 106 (5.22) 0.71 145 (53.20) 12 0.71 Ta 16	Cecum-transverse colon	1799 (61.95)	527 (60.44)	1272 (62.60)	
Multiple 43 (1.4) 10 (1.15) 33 (1.62) Rectum 564 (19.42) 176 (20.18) 388 (19.09) 1 Unknown 37 (1.27) 14 (1.61) 23 (1.13) 1 Grade 23 (1.23) 10 (5.41) 1 Grade II/IV 2342 (80.65) 697 (79.93) 1645 (80.95) 1 Unknown 389 (13.40) 112 (12.44) 277 (13.63) 1 Tumor size 0.882 5 5 cm 1179 (40.60) 360 (41.28) 819 (40.31) 1 '5 cm 1244 (42.84) 370 (42.43) 874 (43.01) 1 1 Unknown 481 (16.56) 142 (16.28) 339 (16.68) 1 1 10 ris 16 (0.55) 4 (0.46) 12 (0.59) 1 1 1 T1 167 (5.75) 61 (7.00) 106 (5.22) 1 1 1 T2 100 (3.44) 35 (4.01) 65 (3.20) 1 1 1 T4 1331 (45.83) 371 (Descending colon–sigmoid	461 (15.87)	145 (16.63)	316 (15.55)	-
Image 564 (19.42) 176 (20.18) 388 (19.09) Unknown 37 (1.27) 14 (1.61) 23 (1.13) 0.155 Grade 0.155 0.155 0.155 Grade IIII 173 (5.96) 63 (7.22) 110 (5.41) 0.155 Grade IIII/IV 2342 (80.65) 697 (79.93) 1645 (80.95) 0.882 Unknown 389 (13.40) 112 (12.84) 277 (13.63) 0.882 \$5 cm 1179 (40.60) 360 (41.28) 819 (40.31) 0.882 \$5 cm 1244 (42.84) 370 (42.43) 874 (43.01) 0.079 Tots 124 (42.84) 370 (42.43) 874 (43.01) 0.079 Tots 126 (0.55) 4 (0.46) 12 (0.59) 0.079 ToTis 16 (0.55) 4 (0.46) 12 (0.59) 0.079 T1 167 (5.75) 61 (7.00) 106 (5.22) 0.016 (5.22) T2 100 (3.44) 35 (4.01) 65 (3.20) 0.173 T4 1331 (45.83) 371 (42.55) 960 (47.24) <	Multiple	43 (1.48)	10 (1.15)	33 (1.62)	-
Intervent Intervent Intervent Intervent Unknown 37 (1.27) 14 (1.61) 23 (1.13) 0.155 Grade 0.155 0.155 Grade I/II 173 (5.96) 63 (7.22) 110 (5.41) 0.155 Grade III/IV 2342 (80.65) 697 (79.93) 1645 (80.95) 0.082 Unknown 389 (13.40) 112 (12.84) 277 (13.63) 0.082 S cran 1179 (40.60) 360 (41.28) 819 (40.31) 117 '5 cm 1244 (42.84) 370 (42.43) 874 (43.01) 0.079 Unknown 481 (16.56) 142 (16.28) 339 (16.68) 0.079 Tots 167 (5.75) 61 (7.00) 106 (5.22) 1.00 T1 167 (5.75) 61 (7.00) 165 (3.20) 1.00 T2 100 (3.41) 35 (4.01) 65 (3.20) 1.00 T4 1331 (45.83) 371 (42.55) 960 (47.24) 1.00 Nstage 0.269 1.00 1.02	Rectum	564 (19.42)	176 (20.18)	388 (19.09)	
International Internat International International	Unknown	37 (1.27)	14 (1.61)	23 (1.13)	
Intervention Intervention Intervention Grade I/II 173 (5.96) 63 (7.22) 110 (5.41) Intervention Grade III/IV 2342 (80.65) 697 (79.93) 1645 (80.95) Intervention Unknown 389 (13.40) 112 (12.84) 277 (13.63) Intervention Tumor size Intervention 360 (41.28) 819 (40.31) Intervention '5 cm 1244 (42.84) 370 (42.43) 874 (43.01) Intervention '5 cm 1244 (42.84) 370 (42.43) 874 (43.01) Intervention '5 cm 1244 (42.84) 370 (42.43) 874 (43.01) Intervention '10 ris 161 (0.55) 14 (0.46) 12 (0.59) Intervention To-Tis 167 (5.75) 61 (7.00) 106 (5.22) Intervention T2 100 (3.44) 35 (4.01) 65 (3.20) Intervention T4 1331 (45.83) 371 (42.55) 960 (47.24) Intervention N stage Intervention 690 (23.76) 197 (22.59) 493 (24.26) Intervention	Grade				0.155
International International International International Grade III/IV 2342 (80.65) 697 (79.93) 1645 (80.95) International Tumor size 0.882 0.882 \$5 cm 1179 (40.60) 360 (41.28) 819 (40.31) 0.882 \$5 cm 1244 (42.84) 370 (42.43) 874 (43.01) 0.079 Unknown 481 (16.56) 142 (16.28) 339 (16.68) 0.079 To Tis 16 (0.55) 4 (0.46) 12 (0.59) 0.079 To Tis 16 (0.55) 4 (0.46) 12 (0.59) 0.079 To Tis 16 (0.55) 4 (0.46) 12 (0.59) 0.079 To Tis 16 (0.55) 4 (0.46) 12 (0.59) 0.079 Tage 100 (3.44) 35 (4.01) 65 (3.20) 0.071 Ta 131 (45.83) 371 (42.55) 960 (47.24) 0.069 Ns tage 131 (45.83) 401 (45.99) 959 (47.19) 0.01 Na tage 1360 (46.83) 401 (45.99) 959 (4	Grade I/II	173 (5 96)	63 (7 22)	110 (5 41)	
Interview Interview Interview Interview Interview Unknown 389 (13.40) 112 (12.84) 277 (13.63) Image (0.882) S5 cm 1179 (40.60) 360 (41.28) 819 (40.31) Image (0.882) '5 cm 1244 (42.84) 370 (42.43) 874 (43.01) Image (0.97) Unknown 481 (16.56) 142 (16.28) 339 (16.68) Image (0.97) To-Tis 16 (0.55) 4 (0.46) 12 (0.59) Image (0.97) To-Tis 16 (0.55) 4 (0.46) 12 (0.59) Image (0.97) To-Tis 16 (0.55) 4 (0.46) 12 (0.59) Image (0.97) T2 100 (3.44) 35 (4.01) 65 (3.20) Image (0.97) T4 1331 (45.83) 371 (42.55) 960 (47.24) Image (0.96) N stage Image (0.96) (23.76) 197 (22.59) 493 (24.26) Image (0.97) N1 690 (23.76) 197 (22.59) 493 (24.26) Image (0.97) Image (0.97) N2 1360 (46.83) 401 (45.99) 959 (47.19)	Grade III/IV	2342 (80 65)	697 (79 93)	1645 (80.95)	
Diamon ize Diamon ize Diamon ize Diamon ize Diamon ize S cm 1179 (40.60) 360 (41.28) 819 (40.31) Diamon ize 'S cm 1244 (42.84) 370 (42.43) 874 (43.01) Diamon ize Unknown 481 (16.56) 142 (16.28) 339 (16.68) Diamon ize T stage	Unknown	389 (13.40)	112 (12 84)	277 (13 63)	
Name1179 (40.60)360 (41.28)819 (40.31)5002 $\leq 5 \text{ cm}$ 1244 (42.84)370 (42.43)874 (43.01)1 2 s cm1244 (42.84)370 (42.43)874 (43.01)1Unknown481 (16.56)142 (16.28)339 (16.68)10.079T0-Tis16 (0.55)4 (0.46)12 (0.59)1T1167 (5.75)61 (7.00)106 (5.22)1T2100 (3.44)35 (4.01)65 (3.20)1T31290 (44.42)401 (45.99)889 (43.75)1T41331 (45.83)371 (42.55)960 (47.24)0.269No854 (29.41)274 (31.42)580 (28.54)1N1690 (23.76)197 (22.59)493 (24.26)1N21360 (46.83)401 (45.99)959 (47.19)1M stage10.7130.7130.713M01827 (62.91)553 (63.42)1274 (62.70)1M11077 (37.09)319 (36.58)758 (37.30)1Surgery336 (11.57)104 (11.93)232 (11.42)1Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)1Total colectomy1728 (59.50)512 (58.72)1216 (59.84)1Lymph node dissection11.77359 (17.67)1No eor biopsy507 (17.46)148 (16.97)359 (17.67)241 to 382 (2.82)22 (2.52)60 (2.95)22 42315 (79.72)702 (80.50)	Tumor size			277 (10100)	0.882
International International International 2 5 cm 1244 (42.84) 370 (42.43) 874 (43.01) Unknown 481 (16.56) 142 (16.28) 339 (16.68) T stage 0.079 To-Tis 16 (0.55) 4 (0.46) 12 (0.59) T1 167 (5.75) 61 (7.00) 106 (5.22) T2 100 (3.44) 35 (4.01) 65 (3.20) T3 1290 (44.42) 401 (45.99) 889 (43.75) T4 1331 (45.83) 371 (42.55) 960 (47.24) N stage 0.269 N0 854 (29.41) 274 (31.42) 580 (28.54) N1 690 (23.76) 197 (22.59) 493 (24.26) N2 1360 (46.83) 401 (45.99) 959 (47.19) M stage 0.713 0.713 0.713 M0 1827 (62.91) 553 (63.42) 1274 (62.70) M1 1077 (37.09) 319 (36.58) 758 (37.30) Surgery 36 (11.57) 104 (11.93) 232 (11.42) No surgery	<5 cm	1179 (40 60)	360 (41 28)	819 (40 31)	0.002
Init (1.1.1.5) 1.1 (1.1.1.5) 1.1 (1.1.1.5) 1.1 (1.1.1.5) Unknown 481 (16.56) 142 (16.28) 339 (16.68) 0.079 T stage 0.079 To-Tis 16 (0.55) 4 (0.46) 12 (0.59) 0.079 T1 167 (5.75) 61 (7.00) 106 (5.22) 100 (3.44) 35 (4.01) 65 (3.20) 107 T2 100 (3.44) 35 (4.01) 65 (3.20) 108	>5 cm	1244 (42.84)	370 (42.43)	874 (43.01)	-
Init (13.5) Init (13.5) <thinit (13.5)<="" th=""> <thinit (13.5)<="" th=""></thinit></thinit>	Unknown	481 (16 56)	142 (16 28)	339 (16.68)	
TorpTorpTorpTorpTorpT0-Tis16 (0.55)4 (0.46)12 (0.59)10T1167 (5.75)61 (7.00)106 (5.22)10T2100 (3.44)35 (4.01)65 (3.20)10T31290 (44.42)401 (45.99)889 (43.75)10T41331 (45.83)371 (42.55)960 (47.24)0.269No854 (29.41)274 (31.42)580 (28.54)10N1690 (23.76)197 (22.59)493 (24.26)10N21360 (46.83)401 (45.99)959 (47.19)10M stage1360 (46.83)401 (45.99)959 (47.19)10M stage1077 (37.09)319 (36.58)758 (37.30)10M11077 (37.09)319 (36.58)758 (37.30)10Surgery336 (11.57)104 (11.93)232 (11.42)10Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)10Ivandor1728 (59.50)512 (58.72)1216 (59.84)11Lymph node dissection507 (17.46)148 (16.97)359 (17.67)0.717None or biopsy507 (17.46)148 (16.97)359 (17.67)11 to 382 (2.82)22 (2.52)60 (2.95)2 ≥ 4 2315 (79.72)702 (80.50)1613 (79.38)0.418	T stage	101 (10.50)	112 (10.20)	555 (10.00)	0.079
To TheTro (10.5)Tro (0.5)Tro (0.5)Tro (0.5)T1 $167 (5.75)$ $61 (7.00)$ $106 (5.22)$ TT2 $100 (3.44)$ $35 (4.01)$ $65 (3.20)$ TT3 $1290 (44.42)$ $401 (45.99)$ $889 (43.75)$ TT4 $1331 (45.83)$ $371 (42.55)$ $960 (47.24)$ 0.269No $854 (29.41)$ $274 (31.42)$ $580 (28.54)$ 0.269N0 $854 (29.41)$ $274 (31.42)$ $580 (28.54)$ 1N1 $690 (23.76)$ $197 (22.59)$ $493 (24.26)$ 1N2 $1360 (46.83)$ $401 (45.99)$ $959 (47.19)$ 1M stage1360 (46.83) $401 (45.99)$ $959 (47.19)$ 1M stage1360 (46.83) $401 (45.99)$ $959 (47.19)$ 1Mo $1827 (62.91)$ $553 (63.42)$ $1274 (62.70)$ 1M1 $1077 (37.09)$ $319 (36.58)$ $758 (37.30)$ 1Surgery $336 (11.57)$ $104 (11.93)$ $232 (11.42)$ 1Local tumor excision/partial colectomy $840 (28.93)$ $256 (29.36)$ $584 (28.74)$ 1Total colectomy $1728 (59.50)$ $512 (58.72)$ $1216 (59.84)$ 1Lymph node dissection $148 (16.97)$ $359 (17.67)$ 0.717 None or biopsy $507 (17.46)$ $148 (16.97)$ $359 (17.67)$ 24 24 $2315 (79.72)$ $702 (80.50)$ $1613 (79.38)$ 0.418	T0-Tis	16 (0.55)	4 (0.46)	12 (0 59)	0.075
11107 (37.9)107 (3.67)100 (3.42)T2100 (3.44)35 (4.01)65 (3.20)T31290 (44.42)401 (45.99)889 (43.75)T41331 (45.83)371 (42.55)960 (47.24)N stage0.269N0854 (29.41)274 (31.42)580 (28.54)N1690 (23.76)197 (22.59)493 (24.26)N21360 (46.83)401 (45.99)959 (47.19)M stage0.713M01827 (62.91)553 (63.42)1274 (62.70)M11077 (37.09)319 (36.58)758 (37.30)Surgery0.8410.841No surgery336 (11.57)104 (11.93)232 (11.42)Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)Lymph node dissection728 (59.50)512 (58.72)1216 (59.84)Lymph node dissection2215 (79.72)702 (80.50)1613 (79.38)242315 (79.72)702 (80.50)1613 (79.38)0.418	T1	167 (5.75)	61 (7.00)	106 (5 22)	
T3129 (44.2)401 (45.99)88 (43.75)T41331 (45.83)371 (42.55)960 (47.24)N stage0.269N0854 (29.41)274 (31.42)580 (28.54)N1690 (23.76)197 (22.59)493 (24.26)N21360 (46.83)401 (45.99)959 (47.19)M stageM01827 (62.91)553 (63.42)1274 (62.70)M11077 (37.09)319 (36.58)758 (37.30)SurgeryNo surgery336 (11.57)104 (11.93)232 (11.42)Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)Total colectomy1728 (59.50)512 (58.72)1216 (59.84)Lymph node dissection0.717None or biopsy507 (17.46)148 (16.97)359 (17.67)1 to 382 (2.82)22 (2.52)60 (2.95)24Chemotherapy315 (79.72)702 (80.50)1613 (79.38)10.418	T'2	100 (3.44)	35 (4 01)	65 (3 20)	
ToTo (1112)To (1112)To (1112)To (1112)To (1112)T41331 (45.83)371 (42.55)960 (47.24)0.269N stage0.269N0854 (29.41)274 (31.42)580 (28.54)N1690 (23.76)197 (22.59)493 (24.26)N21360 (46.83)401 (45.99)959 (47.19)M stage0.713M01827 (62.91)553 (63.42)1274 (62.70)M11077 (37.09)319 (36.58)758 (37.30)Surgery0.841No surgery336 (11.57)104 (11.93)232 (11.42)Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)Total colectomy1728 (59.50)512 (58.72)1216 (59.84)Lymph node dissection0.717None or biopsy507 (17.46)148 (16.97)359 (17.67)1 to 382 (2.82)22 (2.52)60 (2.95)≥42315 (79.72)702 (80.50)1613 (79.38)Chemotherapy5059.712702 (80.50)1613 (79.38)	T3	1290 (44 42)	401 (45 99)	889 (43 75)	-
N11001 (10.00)0.01 (10.00)0.00 (10.21)0.06N stage0.269N0854 (29.41)274 (31.42)580 (28.54)N1690 (23.76)197 (22.59)493 (24.26)N21360 (46.83)401 (45.99)959 (47.19)M stage0.713M01827 (62.91)553 (63.42)1274 (62.70)M11077 (37.09)319 (36.58)758 (37.30)Surgery0.841No surgery336 (11.57)104 (11.93)232 (11.42)Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)Total colectomy1728 (59.50)512 (58.72)1216 (59.84)Lymph node dissection0.717None or biopsy507 (17.46)148 (16.97)359 (17.67)1 to 382 (2.82)22 (2.52)60 (2.95)≥42315 (79.72)702 (80.50)1613 (79.38)0.418	T4	1331 (45.83)	371 (42 55)	960 (47 24)	
Non854 (29.41)274 (31.42)580 (28.54)N1690 (23.76)197 (22.59)493 (24.26)N21360 (46.83)401 (45.99)959 (47.19)M stage1360 (46.83)401 (45.99)959 (47.19)M stage1827 (62.91)553 (63.42)1274 (62.70)M11077 (37.09)319 (36.58)758 (37.30)Surgery336 (11.57)104 (11.93)232 (11.42)No surgery336 (11.57)104 (11.93)232 (11.42)Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)Total colectomy1728 (59.50)512 (58.72)1216 (59.84)Lymph node dissection1728 (59.50)512 (58.72)1216 (59.84)I to 382 (2.82)22 (2.52)60 (2.95)1≥42315 (79.72)702 (80.50)1613 (79.38)0.418	N stage	1551 (15.65)	5/1 (12.55)	500 (17.21)	0.269
N1690 (23.76)197 (22.59)493 (24.26)N21360 (46.83)401 (45.99)959 (47.19)M stage0.713M01827 (62.91)553 (63.42)1274 (62.70)M11077 (37.09)319 (36.58)758 (37.30)Surgery0.8410.841No surgery336 (11.57)104 (11.93)232 (11.42)Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)Total colectomy1728 (59.50)512 (58.72)1216 (59.84)Lymph node dissection0.7170.717None or biopsy507 (17.46)148 (16.97)359 (17.67)1 to 382 (2.82)22 (2.52)60 (2.95)242 at the disterior702 (80.50)1613 (79.38)0.418	NO	854 (29 41)	274 (31 42)	580 (28 54)	0.209
N11360 (25.79)137 (22.57)135 (21.29)N21360 (46.83)401 (45.99)959 (47.19)0.713M stage0.713M01827 (62.91)553 (63.42)1274 (62.70)M11077 (37.09)319 (36.58)758 (37.30)Surgery0.841No surgery336 (11.57)104 (11.93)232 (11.42)Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)Total colectomy1728 (59.50)512 (58.72)1216 (59.84)Lymph node dissection0.717None or biopsy507 (17.46)148 (16.97)359 (17.67)1 to 382 (2.82)22 (2.52)60 (2.95)≥42315 (79.72)702 (80.50)1613 (79.38)Chemotherapy0.4180.418	NI	690 (23 76)	197 (22 59)	493 (24 26)	
N2100 (10.05)101 (10.05)100 (10.05)M stage0.713M01827 (62.91)553 (63.42)1274 (62.70)M11077 (37.09)319 (36.58)758 (37.30)Surgery0.841No surgery336 (11.57)104 (11.93)232 (11.42)Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)Total colectomy1728 (59.50)512 (58.72)1216 (59.84)Lymph node dissection0.717None or biopsy507 (17.46)148 (16.97)359 (17.67)1 to 382 (2.82)22 (2.52)60 (2.95)≥42315 (79.72)702 (80.50)1613 (79.38)Chemotherapy0.418	N2	1360 (46 83)	401 (45 99)	959 (47 19)	-
M stage1827 (62.91)553 (63.42)1274 (62.70)M11077 (37.09)319 (36.58)758 (37.30)Surgery104 (11.93)232 (11.42)No surgery336 (11.57)104 (11.93)232 (11.42)Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)Total colectomy1728 (59.50)512 (58.72)1216 (59.84)Lymph node dissection607 (17.46)148 (16.97)359 (17.67)None or biopsy507 (17.46)148 (16.97)359 (17.67)1 to 382 (2.82)22 (2.52)60 (2.95)24Chemotherapy702 (80.50)1613 (79.38)0.418	M stage	1500 (10.05)		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0.713
IntermIntermIntermIntermIntermIntermIntermM11077 (37.09)319 (36.58)758 (37.30)0.841Surgery336 (11.57)104 (11.93)232 (11.42)0.841No surgery336 (11.57)104 (11.93)232 (11.42)0.841Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)0.717Total colectomy1728 (59.50)512 (58.72)1216 (59.84)0.717None or biopsy507 (17.46)148 (16.97)359 (17.67)0.717I to 382 (2.82)22 (2.52)60 (2.95)0.418 ≥ 4 2315 (79.72)702 (80.50)1613 (79.38)0.418	Mo	1827 (62 91)	553 (63.42)	1274 (62 70)	0.715
Init107 (97.07)517 (06.07)719 (07.07)Surgery \sim \sim 0.841No surgery336 (11.57)104 (11.93)232 (11.42)Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)Total colectomy1728 (59.50)512 (58.72)1216 (59.84)Lymph node dissection \sim 0.717None or biopsy507 (17.46)148 (16.97)359 (17.67)1 to 382 (2.82)22 (2.52)60 (2.95)≥42315 (79.72)702 (80.50)1613 (79.38)Chemotherapy \sim \sim 0.418	MI	1027 (02.91)	319 (36 58)	758 (37 30)	-
No surgery336 (11.57)104 (11.93)232 (11.42)Local tumor excision/partial colectomy840 (28.93)256 (29.36)584 (28.74)Total colectomy1728 (59.50)512 (58.72)1216 (59.84)Lymph node dissection 0.717 None or biopsy507 (17.46)148 (16.97)359 (17.67)1 to 382 (2.82)22 (2.52)60 (2.95) ≥ 4 2315 (79.72)702 (80.50)1613 (79.38)0.418	Surgery	2017 (31.07)		, 55 (57.50)	0.841
Local tumor excision/partial colectomy 840 (28.93) 256 (29.36) 584 (28.74) Total colectomy 1728 (59.50) 512 (58.72) 1216 (59.84) 0.717 None or biopsy 507 (17.46) 148 (16.97) 359 (17.67) 0.717 1 to 3 82 (2.82) 22 (2.52) 60 (2.95) 1 ≥ 4 2315 (79.72) 702 (80.50) 1613 (79.38) 0.418	No surgery	336 (11 57)	104 (11 93)	232 (11 42)	0.011
Total colectomy 1728 (59.50) 512 (58.72) 1216 (59.84) Lymph node dissection 0.717 None or biopsy 507 (17.46) 148 (16.97) 359 (17.67) 1 to 3 82 (2.82) 22 (2.52) 60 (2.95) ≥ 4 2315 (79.72) 702 (80.50) 1613 (79.38)	Local tumor excision/partial colectory	840 (28 93)	256 (29.36)	584 (28 74)	+
Num correction1726 (59.50)512 (59.72)1216 (59.64)Lymph node dissection 0.717 None or biopsy507 (17.46)148 (16.97)359 (17.67)1 to 382 (2.82)22 (2.52)60 (2.95) ≥ 4 2315 (79.72)702 (80.50)1613 (79.38)Chemotherapy 0.418	Total colectomy	1728 (59 50)	512 (58 72)	1216 (59.84)	+
Dynamic dissection 0./17 None or biopsy 507 (17.46) 148 (16.97) 359 (17.67) 1 to 3 82 (2.82) 22 (2.52) 60 (2.95) ≥4 2315 (79.72) 702 (80.50) 1613 (79.38) Chemotherapy 0.418	Lymph node dissection	1120 (39.30)	512 (50.72)	1210 (39.04)	0.717
Note of biopsy $307 (17.40)$ $140 (10.57)$ $359 (17.67)$ 1 to 3 $82 (2.82)$ $22 (2.52)$ $60 (2.95)$ ≥ 4 $2315 (79.72)$ $702 (80.50)$ $1613 (79.38)$ Chemotherapy 0.418	None or biopsy	507 (17 46)	148 (16 97)	359 (17 67)	0./1/
$02 (2.02)$ $22 (2.32)$ $00 (2.55)$ ≥ 4 2315 (79.72) 702 (80.50) 1613 (79.38) Chemotherapy 0.418		82 (2 82)	22 (2 52)	60 (2.95)	+
2-1 2515 (75.72) 702 (80.50) 1015 (79.58) Chemotherapy 0.418	>4	2315 (79 72)	702 (80 50)	1613 (70.38)	+
		2313 (79.72)	/02 (00.30)	1013 (/7.30)	0.419
Continued	Continued				0.410

Variables	All patients N (%)	Validation set N (%)	Training set N (%)	P value
No/unknown	1216 (41.87)	375 (43.00)	841 (41.39)	
Yes	1688 (58.13)	497 (57.00)	1191 (58.61)	
Radiotherapy				0.751
No/unknown	2502 (86.16)	754 (86.47)	1748 (86.02)	
Yes	402 (13.84)	118 (13.53)	284 (13.98)	

Table 1. Patient demographics and pathological characteristics.

yielded similar discrimination. The 3-year and 5- year tAUCs of the prognostic model in the training set were 0.829(0.812-0.850) and 0.839 (0.820-0.860), respectively.

Discussion

A prognostic nomogram for 3- and 5-year OS prediction was constructed and validated in our study. We analyzed 2904 colorectal SRCC patients from SEER dataset, followed by constructing a nomogram for 3- and 5-year OS prediction. In addition, internal and external validation of the nomogram demonstrated favorable calibration as well as discrimination. Moreover, our established nomogram showed more potent predictive capacity compared to SEER summary stage or TNM staging systems, which could be readily applied in clinical practice to assist patient counseling as well as individualized therapy.

Some independent factors for predicting prognosis were incorporated into our constructed nomogram. Besides, the survival was also analyzed based on the colorectal SRCC stage, which discovered that early stage patients had better prognosis than those at the advanced stage, and such results conformed to almost every study^{27,28}. Ishihara and colleagues discovered that primary location might serve as the independent factor for prognosis prediction²⁹. Typically, both tumor stage and primary location were identified as the prognostic factors in the present work. Moreover, this study identified tumor size and pathological grade as the independent prognostic factors for colorectal SRCC.

It is necessary to conduct multidisciplinary treatment of colorectal SRCC, so as to select the best therapeutic strategy, and it should be noted that surgery is significant to treat the localized tumors³⁰. As suggested by a population-based study that enrolls 1972 colorectal SRCC patients between 1989 and 2010 to evaluate whether adjuvant chemotherapy is significant, adjuvant chemotherapy can offer survival benefits to stage III colon SRCC patients³¹. Tao Shi and coworkers also discovered that chemotherapy was linked with the superior survival of colorectal SRCC with distant metastasis³². Findings in this work also verified that both chemotherapy and surgery played important roles in diagnosing colorectal SRCC. Further, the surgical retrieval of at least 4 regional lymph nodes markedly enhanced patient survival. The above-mentioned factors remarkably impacted colorectal SRCC prognosis. Using our constructed nomogram, patients suffering from diverse tumor differentiation degrees were assigned with different scores and then with diverse survival outcomes, even though they might be at the same TNM stage. Besides, these results explicitly clarified the difference between the prognosis estimated using our constructed nomogram and that estimated by the TNM classification systems, which might explain the better ability of our nomogram in predicting OS than the TNM classification systems.

Previous studies have also explored nomograms in colorectal signet ring cell carcinoma^{33,34}. Wang et al. retrospectively evaluated the patient records of mucinous adenocarcinoma and SRCC patients aged \leq 40 years³⁴. A nomogram predicting OS was created for risk quantitation. However, compared with our study, the number of cases enrolled in the previous study was still too small, and only included patients aged \leq 40 years. Our study may be more comprehensive and practical.

As a statistical method, the nomogram is capable of providing survival possibility by formula calculation^{35,36}. Nomogram has been validated to harbor superior predictive capacity in comparison with TNM stage system in certain types of malignant tumors, which is considered as an alternative or even a novel standard^{37,38}. In particular, it is proper to use nomogram to handle complicated situations without clinical guidelines. And it is convenient and simple to utilize nomogram for survival prediction. To begin with, in a nomogram, from each clinicopathological parameter, a vertical line is drawn to "scores" line, followed by score addition to give rise to "total scores". Therefore, certain recommendation could accordingly be offer by clinicians. For instance, operation is suggested in well-differentiated populations in consideration of satisfactory prognosis. On the contrary, palliative chemotherapy is preferred in poorly-differentiated populations in consideration of decreased life expectancy. Thus, the presently established nomogram could help to choose patients with prolonged survival, who might benefit from palliative resection.

Several advantages exist in our research. The detailed clinicopathological data of colorectal SRCC from SEER database ensured that we successfully constructed a precise prognostic nomogram. Moreover, superior discriminative capacity for OS prediction is detected in our nomogram compared to SEER summary stage and TNM stage systems. Additionally, available clinical parameters are used, which is convenient for nomogram application.

Certain limitations should be noted in this population-based study. First of all, selection bias was inevitable due to the retrospective nature. Secondly, prognostic information, including the microsatellite stability/micro-satellite instability (MSS/MSI) status, the RAS/BRAF/MSI status, family history, vascular invasion and patient condition, was not available in the SEER database, and future research should focus on these aspects. Thirdly, the convincing external verification was lacking in this work. At last, our constructed nomogram, which might

	Univariate analysis	Multivariate analysi	6
Variable	P value	HR (95% CI)	P value
Year at diagnosis	0.801		NI
2004-2007			
2008-2011			
2012-2015			
Insured status	0.532		NI
Uninsured/unknown			
Any medicaid/insured			
Age	0.001		
<65		Reference	
≥65		1.622 (1.452, 1.813)	< 0.001
Marital status ^a	< 0.001		
Unmarried		Reference	
Married		0.869 (0.783, 0.964)	0.008
Gender	0.842	,	NI
Female			
Male			
Race	0.143		NI
Black	0.110		
White			
Other			
Primary site	< 0.001		
Cecum_transverse colon	< 0.001	Reference	
Descending colon sigmoid		1 188 (1 020 1 385)	0.027
Multiple		1.188 (1.020, 1.383)	0.027
Pactum		1.400 (0.907, 2.044)	0.074
Unknown		1.227 (1.035, 1.434)	0.010
Crada	< 0.001	1.237 (0.773, 1.974)	0.372
	< 0.001	Defener ee	
		Reference	0.015
		1.364 (1.061, 1.753)	0.015
Temeneire	<0.001	1.407 (1.000, 1.808)	0.018
	< 0.001	Defenence	
			0.207
5 cm		0.950 (0.845, 1.067)	0.387
Unknown	.0.001	1.197 (1.016, 1.411)	0.032
1 stage	< 0.001	Defense	
10-115		Reference	0.010
11		1.134 (0.387, 3.324)	0.819
12		1.881 (0.679, 5.209)	0.224
13		2.330 (0.861, 6.304)	0.096
14		3.306 (1.221, 8.952)	0.019
N stage	< 0.001	D.C.	< 0.001
NO		Reference	0.004
NI		1.716 (1.457, 2.021)	< 0.001
N2		2.898 (2.479, 3.388)	< 0.001
M stage	< 0.001		
MO		Reference	
M1		2.377 (2.104, 2.685)	< 0.001
Surgery	< 0.001		< 0.001
No surgery		Reference	
Local tumor excision/partial colectomy		0.468 (0.365, 0.599)	< 0.001
Total colectomy		0.552 (0.429, 0.712)	< 0.001
Lymph node dissection	< 0.001		< 0.001
None or Biopsy		Reference	
1 to 3		0.782 (0.561, 1.091)	0.148
≥ 4		0.573 (0.462, 0.710)	< 0.001
Continued			

	Univariate analysis	Multivariate analysis		
Variable	P value	HR (95% CI)	P value	
Chemotherapy	0.002			
No/unknown		Reference		
Yes		0.583 (0.519, 0.654)	< 0.001	
Radiotherapy	0.280			
No/unknown				
Yes				

Table 2. Univariate and multivariate analyses of overall survival (OS) for patients in training set. *NI* not included in the multivariate survival analysis, ^amarital status was used as an adjusted factor in multivariate analysis.

Points	0	10	20		0	40	50	60		0	80	90	
Ago at diagnosia						≥65							
Age at diagnosis	<65												
Primary site	de	scending	colon–si	gmoid									
cecur	n-transvers		rectum	ا/grade III	iuitipie IV								
Grade	grade I/II			unkne	own								
Tumor size	>5	5cm											
	≤5cm	τ4	unknov	wn					-	0			
T stage		I							I	J			
	10-115						N1						14
N stage	NO						1					N2	
M stage										M1			
	M0	total c	olectomy										
Surgery local tumor e	excision /pa	rtial cole	ctomv					r	no surae	rv			
Lymph node dispection			,	1 to 3	;					.,			
Lymph hode dissection	≥4					none	or biopsy						
Chemotherapy	yes					nc	/unknown						
Total Points													,
	0	50	100	150	200	250	300	350	400	450	500	550	600
3-year OS		0.9	0.	8 0.7	0.6 0.	.5 0.4 0.	3 0.2 0.1						
5-year OS		0.9	0.8			4030	2 0 1						
Figure	e 2. Nomo	ogram to	predict 3	3-year (<i>A</i>	A) and 5	5-year (1	B) overall	surviva	al (OS) o	of color	ectal SRC	CC patier	ıts.

	Training set		Validation set		
Classification	C-index (95% CI)	<i>P</i> value*	C-index (95% CI)	P value*	
Nomogram	0.743 (0.730, 0.755)		0.730 (0.710, 0.751)		
AJCC 8th stage	0.651(0.637, 0.665)	< 0.001	0.650 (0.627, 0.673)	< 0.001	
SEER summary stage	0.645 (0.631, 0.659)	< 0.001	0.639 (0.617, 0.661)	< 0.001	

Table 3. C-indexes for the nomogram and other stage systems in patients with colorectal signet ring cell carcinoma. *All are compared with Nomogram, *HR* hazard ratio, *CI* confidence interval.









serve as a user-friendly approach for the decision-making of doctors, did not incorporate each prognostic factors or always offer accurate prognosis prediction in clinical practice.

Conclusion

In conclusion, for patients with colorectal SRCC, we established and validated a nomogram to predict 3-and 5-year OS based on a large, population-based cohort. The nomogram showed excellent performance and could be thought of as a practical tool to predict prognosis. Nevertheless, further mining of the uncertain prognostic parameters for the optimization of nomogram is still needed, which requires in-depth external validation.

Received: 29 August 2020; Accepted: 27 January 2021 Published online: 09 February 2021

References

- 1. El-Shami, K. *et al.* American cancer society colorectal cancer survivorship care guidelines. *CA A Cancer J. Clin.* **65**, 428–455. https://doi.org/10.3322/caac.21286 (2015).
- Korphaisarn, K. *et al.* Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br. J. Cancer 121, 505–510. https://doi.org/10.1038/s41416-019-0548-9 (2019).
- Nitsche, U. et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann. Surg. 258, 775–782. https://doi.org/10.1097/SLA.0b013e3182a69f7e (2013).
- Mizushima, T. *et al.* Primary colorectal signet-ring cell carcinoma: clinicopathological features and postoperative survival. *Surg. Today* 40, 234–238. https://doi.org/10.1007/s00595-009-4057-y (2010).
- Meng, Z. W., Pan, W., Hong, H. J., Chen, J. Z. & Chen, Y. L. Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems. *Medicine* 96, e7891. https://doi.org/10.1097/ md.000000000007891 (2017).
- Arifi, S., Elmesbahi, O. & Amarti Riffi, A. Primary signet ring cell carcinoma of the colon and rectum. Bull. Cancer 102, 880–888. https://doi.org/10.1016/j.bulcan.2015.07.005 (2015).
- Burke, H. B. Outcome prediction and the future of the TNM staging system. J. Natl. Cancer Inst. 96, 1408–1409. https://doi. org/10.1093/jnci/djh293 (2004).
- Belli, S. et al. Outcomes of surgical treatment of primary signet ring cell carcinoma of the colon and rectum: 22 cases reviewed with literature. Int. Surg. 99, 691–698. https://doi.org/10.9738/intsurg-d-14-00067.1 (2014).
- Bademci, R., Bollo, J., Martinez, M. C., Hernadez, M. P. & Targarona, E. M. Colorectal cancer prognosis: the impact of signet ring cell. Gastrointest. Tumors 6, 57–63. https://doi.org/10.1159/000501454 (2019).
- Fang, C. et al. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Br. J. Cancer 117, 1544–1550. https://doi.org/10.1038/bjc.2017.315 (2017).
- Song, W. et al. Development and validation of a nomogram for predicting survival in patients with gastrointestinal stromal tumours. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 44, 1657–1665. https://doi.org/10.1016/j.ejso.2018.07.004 (2018).
- Dai, D., Jin, H. & Wang, X. Nomogram for predicting survival in triple-negative breast cancer patients with histology of infiltrating duct carcinoma: a population-based study. Am. J. Cancer Res. 8, 1576–1585 (2018).
- 13. Huang, J. *et al.* Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection. *Cancer Med.* https://doi.org/10.1002/cam4.2944 (2020).
- 14. Zhou, Y. *et al.* Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer-specific survival of patients with kidney cancer. *Cancer Med.* https://doi.org/10.1002/cam4.2916 (2020).
- Yu, J. B., Gross, C. P., Wilson, L. D. & Smith, B. D. NCI SEER public-use data: applications and limitations in oncology research. Oncol. (Williston Park, NY) 23, 288–295 (2009).
- Cahill, K. S. & Claus, E. B. Treatment and survival of patients with nonmalignant intracranial meningioma: results from the Surveillance, epidemiology, and end results program of the national cancer institute. Clinical article. J. Neurosurg. 115, 259–267. https://doi.org/10.3171/2011.3.jns101748 (2011).
- 17. Liu, Y. L. *et al.* Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database. *Breast Cancer Res. Treat.* **178**, 379–388. https://doi.org/10.1007/s10549-019-05385 -8 (2019).
- Nitsche, U. et al. Prognosis of mucinous and signet-ring cell colorectal cancer in a population-based cohort. J. Cancer Res. Clin. Oncol. 142, 2357–2366. https://doi.org/10.1007/s00432-016-2224-2 (2016).
- 19. Wu, S. G. *et al.* Survival in signet ring cell carcinoma varies based on primary tumor location: a surveillance, epidemiology, and end results database analysis. *Expert Rev. Gastroenterol. Hepatol.* **12**, 209–214. https://doi.org/10.1080/17474124.2018.1416291 (2018).
- Lv, X. et al. A nomogram for predicting bowel obstruction in preoperative colorectal cancer patients with clinical characteristics. World J. Surg. Oncol. 17, 21. https://doi.org/10.1186/s12957-019-1562-3 (2019).
- 21. Shi, T. *et al.* Chemotherapy is associated with increased survival from colorectal signet ring cell carcinoma with distant metastasis: a surveillance, epidemiology, and end results database analysis. *Cancer Med.* **8**, 1930–1940. https://doi.org/10.1002/cam4.2054 (2019).
- Wei, F. & Lyu, H. Postoperative radiotherapy improves survival in gastric signet-ring cell carcinoma: a SEER database analysis. J. Gastric Cancer 19, 393–407. https://doi.org/10.5230/jgc.2019.19.e36 (2019).
- Kim, S. E. et al. Sex- and gender-specific disparities in colorectal cancer risk. World J. Gastroenterol. 21, 5167–5175. https://doi. org/10.3748/wjg.v21.i17.5167 (2015).
- Yang, L. L., Wang, M. & He, P. Clinicopathological characteristics and survival in colorectal signet ring cell carcinoma: a populationbased study. Sci. Rep. 10, 10460. https://doi.org/10.1038/s41598-020-67388-6 (2020).
- Diao, J. D. et al. Construction and validation of a nomogram to predict overall survival in patients with inflammatory breast cancer. Cancer Med. 8, 5600–5608. https://doi.org/10.1002/cam4.2470 (2019).
- Wolbers, M., Koller, M. T., Witteman, J. C. & Steyerberg, E. W. Prognostic models with competing risks: methods and application to coronary risk prediction. *Epidemiol. (Cambridge, Mass)* 20, 555–561. https://doi.org/10.1097/EDE.0b013e3181a39056 (2009).
- Thota, R., Fang, X. & Subbiah, S. Clinicopathological features and survival outcomes of primary signet ring cell and mucinous adenocarcinoma of colon: retrospective analysis of VACCR database. J. Gastrointest. Oncol. 5, 18–24. https://doi.org/10.3978/j. issn.2078-6891.2013.051 (2014).
- 28. Hyngstrom, J. R. *et al.* Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the national cancer data base. *Ann. Surg. Oncol.* **19**, 2814–2821. https://doi.org/10.1245/s10434-012-2321-7 (2012).
- 29. Ishihara, S. *et al.* Tumor location is a prognostic factor in poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the colon. *Int. J. Colorectal Dis.* **27**, 371–379. https://doi.org/10.1007/s00384-011-1343-0 (2012).
- Ling, C. R., Wang, R., Wang, M. J., Ping, J. & Zhuang, W. Prognosis and value of preoperative radiotherapy in locally advanced rectal signet-ring cell carcinoma. Sci. Rep. 7, 45334. https://doi.org/10.1038/srep45334 (2017).
- Hugen, N. *et al.* Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. *Int. J. Cancer* 136, 333–339. https://doi.org/10.1002/ijc.28981 (2015).
- 32. Shi, T. *et al.* Chemotherapy is associated with increased survival from colorectal signet ring cell carcinoma with distant metastasis: a surveillance epidemiology, and end results database analysis. *Cancer Med.* **8**, 1930–1940. https://doi.org/10.1002/cam4.2054 (2019).
- Simkens, G. A. *et al.* Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC. *Ann. Surg. Oncol.* 23, 4214–4221. https://doi.org/10.1245/s10434-016-5211-6 (2016).
- Wang, B. & Zeng, J. Using nomograms to predict prognostic factors in young colorectal mucinous and signet-ring cell adenocarcinoma patients. *Biosci. Rep.* https://doi.org/10.1042/bsr20181863 (2019).

- Balachandran, V. P., Gonen, M., Smith, J. J. & DeMatteo, R. P. Nomograms in oncology: more than meets the eye. *Lancet Oncol.* 16, e173-180. https://doi.org/10.1016/s1470-2045(14)71116-7 (2015).
- Bochner, B. H., Kattan, M. W. & Vora, K. C. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 24, 3967–3972. https://doi.org/10.1200/jco.2005.05.3884 (2006).
- Wang, Y. et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 31, 1188–1195. https://doi.org/10.1200/jco.2012.41.5984 (2013).
- 38. Cao, J. et al. Clinical nomogram for predicting survival of esophageal cancer patients after esophagectomy. Sci. Rep. 6, 26684. https://doi.org/10.1038/srep26684 (2016).

Author contributions

Y.Y. conceived the study. J.D. searched the database and literature. L.M, C.W. and X.L. discussed and analyzed the data. J.D. and L.S. wrote the manuscript. X.S., H.B., Y.Y., B.B. and H.Y. revised the manuscript. All authors approved the final version.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at (https://doi. org/10.1038/s41598-021-82978-8).

Correspondence and requests for materials should be addressed to L.S. or Y.Y.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021